Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
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
P4QU2G3yV2J2wmJ9
